Malignant neoplasm of breast
|
0.370 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
Meconium Aspiration Syndrome
|
0.210 |
Biomarker
|
phenotype |
MGD |
|
|
|
Congenital anomaly of cartilage
|
0.200 |
Biomarker
|
group |
MGD |
|
|
|
Osteochondrodysplasias
|
0.200 |
Biomarker
|
group |
MGD |
|
|
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Furthermore, the levels of CRE-BP1 mRNA in some clinical samples of human tumors were apparently higher than that in normal tissues.
|
1829805 |
1991 |
Adult T-Cell Lymphoma/Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Sequence requirements of ATF2 and CREB binding to the human T-cell leukemia virus type 1 LTR R region.
|
8610463 |
1996 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Our results suggest that ATF2 is a regulator of radiation and drug resistance in melanomas, and that tumor targeted ATF2 modulators may be useful sensitizers in the treatment of tumors of this type.
|
9484842 |
1998 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results suggest that ATF2 is a regulator of radiation and drug resistance in melanomas, and that tumor targeted ATF2 modulators may be useful sensitizers in the treatment of tumors of this type.
|
9484842 |
1998 |
Transient Ischemic Attack
|
0.200 |
Biomarker
|
disease |
RGD |
Rapid and long-lasting suppression of the ATF-2 transcription factor is a common response to neuronal injury.
|
9813301 |
1998 |
Transient Ischemic Attack
|
0.200 |
Biomarker
|
disease |
RGD |
Persistent phosphorylation of cyclic AMP responsive element-binding protein and activating transcription factor-2 transcription factors following transient cerebral ischemia in rat brain.
|
10077326 |
1999 |
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Taken together, our findings suggest that ATF2 contributes to UVC-induced apoptosis through transcriptional silencing of TNFalpha, which balances Fas-mediated cell death in melanoma.
|
10318823 |
1999 |
Meconium Aspiration Syndrome
|
0.210 |
GeneticVariation
|
phenotype |
BEFREE |
Mouse ATF-2 null mutants display features of a severe type of meconium aspiration syndrome.
|
10364225 |
1999 |
Respiratory Distress Syndrome, Newborn
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The ATF-2 null mutants should enhance our understanding of the mechanism of severe neonatal respiratory distress.
|
10364225 |
1999 |
Malignant Neoplasms
|
0.370 |
Biomarker
|
group |
BEFREE |
These results indicate a novel role for ATF-2 in cancer cell proliferation and suggest a potential feedback mechanism that regulates MAPK signaling.
|
11062705 |
2000 |
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
These results indicate a novel role for ATF-2 in cancer cell proliferation and suggest a potential feedback mechanism that regulates MAPK signaling.
|
11062705 |
2000 |
Hypertensive disease
|
0.200 |
Biomarker
|
group |
RGD |
Activation of cardiac c-Jun NH(2)-terminal kinases and p38-mitogen-activated protein kinases with abrupt changes in hemodynamic load.
|
11358932 |
2001 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
To assess the role of the ATF-2 gene as a tumor suppressor in human carcinogenesis, we examined genetic alterations of the ATF-2 gene in 9 breast cancer cell lines, 10 neuroblastoma cell lines and 46 lung cancer cell lines.
|
11836564 |
2002 |
Malignant neoplasm of breast
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
Genetic variants of the ATF-2 gene were detected in 5 of the 46 (10.6%) lung cancers, but not in neuroblastomas and breast cancers.
|
11836564 |
2002 |
Breast Carcinoma
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
To assess the role of the ATF-2 gene as a tumor suppressor in human carcinogenesis, we examined genetic alterations of the ATF-2 gene in 9 breast cancer cell lines, 10 neuroblastoma cell lines and 46 lung cancer cell lines.
|
11836564 |
2002 |
Carcinogenesis
|
0.070 |
GeneticVariation
|
phenotype |
BEFREE |
To assess the role of the ATF-2 gene as a tumor suppressor in human carcinogenesis, we examined genetic alterations of the ATF-2 gene in 9 breast cancer cell lines, 10 neuroblastoma cell lines and 46 lung cancer cell lines.
|
11836564 |
2002 |
Malignant neoplasm of lung
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Genetic variants of the ATF-2 gene were detected in 5 of the 46 (10.6%) lung cancers, but not in neuroblastomas and breast cancers.
|
11836564 |
2002 |
Carcinoma of lung
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Infrequent mutations of the activating transcription factor-2 gene in human lung cancer, neuroblastoma and breast cancer.
|
11836564 |
2002 |
Primary malignant neoplasm of lung
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Infrequent mutations of the activating transcription factor-2 gene in human lung cancer, neuroblastoma and breast cancer.
|
11836564 |
2002 |
Neuroblastoma
|
0.020 |
GeneticVariation
|
disease |
LHGDN |
Genetic variants of the ATF-2 gene were detected in 5 of the 46 (10.6%) lung cancers, but not in neuroblastomas and breast cancers.
|
11836564 |
2002 |
Neuroblastoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Genetic variants of the ATF-2 gene were detected in 5 of the 46 (10.6%) lung cancers, but not in neuroblastomas and breast cancers.
|
11836564 |
2002 |